REG - Scancell Hlds - Scancell to present at 20th SMR Congress

Scancell HoldingsAnnouncement

10/11/2023 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231110:nRSJ0883Ta&default-theme=true

RNS Number : 0883T  Scancell Holdings Plc  10 November 2023

10 November 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Scancell presents positive data from the first stage in its Phase 2 SCOPE
trial at the 20(th) International Congress of the Society for Melanoma
Research

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, announces that data from the
first stage in its Phase 2 SCOPE trial, investigating SCIB1 in combination
with checkpoint inhibitors (CPIs) in advanced melanoma, was presented at the
20th International Congress of the Society for Melanoma Research
(https://smrcongress.org/) which took place on 6-9 November 2023 in
Philadelphia, PA.

 

The title, timing and location of the presentation are as follows:

 

Poster presentation title     A DNA plasmid melanoma cancer vaccine,
SCIB1, combined with nivolumab+ ipilimumab in patients with advanced
unresectable melanoma: Efficacy and safety results from the open-label Phase 2
SCOPE trial

Presenting Author                     Fayaz Master

Session name                            Late
breaking Clinical Abstracts

Session date and time              11:00am - 11:15am EDT, Thursday
November 9th, 2023

 

 

The abstract of the presentation will be made available on Scancell's website
at: https://www.scancell.co.uk/vaccine-publications
(https://www.scancell.co.uk/vaccine-publications)

 

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                                Tel.: +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com

 

About the SCOPE Phase 2 clinical trial

 

SCOPE is an open label, multicohort, multicentre, Phase 2 study of SCIB1 in
patients with advanced unresectable melanoma receiving either nivolumab with
ipilimumab or pembrolizumab. SCIB1 is a deoxyribonucleic acid (DNA) plasmid
vaccine encoding two CD8 epitopes from the melanoma antigens
tyrosinase-related protein-2 and glycoprotein 100 (gp100), plus two CD4
epitopes from gp100.   The purpose of the study is to determine whether the
addition of SCIB1 to standard of care CPIs can improve the objective response
rate (ORR) of patients with advanced melanoma relative to the CPIs alone. The
ORR is defined as the proportion of patients with a complete or partial
response at any time after the start of treatment.  During the first stage of
the SCOPE trial reported here, patients received SCIB1 in combination with the
best treatment currently available, namely the CPIs nivolumab and ipilimumab.
The First Stage milestone was designed to demonstrate at least a 70% ORR with
an 80% power i.e. at least 9/15 patients responding, assessed by radiological
imaging. Further information relating to the clinical trial can be found on
the Company's website at https://www.scancell.co.uk

and at https://classic.clinicaltrials.gov/ct2/show/NCT04079166
(https://classic.clinicaltrials.gov/ct2/show/NCT04079166)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSASEDSEDF